Page 48 - 2021_02-Haematologica-web

F. Bernardi and G. Mariani et al.
78. Bern M, Nilsen J, Ferrarese M, et al. An
engineered human albumin enhances half- life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med. 2020;12(565):eabb0580.
79. Marcos-Contreras OA, Smith SM, Bellinger DA, et al. Sustained correction of FVII defi- ciency in dogs using AAV-mediated expres- sion of zymogen FVII. Blood. 2016;127(5): 565-571.
80.Miller GJ. Dietary fatty acids and the haemostatic system. Atherosclerosis. 2005; 179(2):213-227.
81.Moor E, Silveira A, van't Hooft F, et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol. 1995;15(5):655-664.
82. Kamikubo Y, Mendolicchio GL, Zampolli A, et al. Selective factor VIII activation by the tissue factor–factor VIIa–factor Xa com- plex Blood. 2017; 130(14):1661-1670.
83. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the gen- eration of activated factor X in the presence of tissue factor and activated factor VII. Haematologica. 2010;95(11):1927-1934.
84. D'Alessandro E, Posma JJN, Spronk HMH, Ten Cate H. Tissue Factor (:Factor VIIa) in the heart and vasculature: more than an envelope. Thromb Res. 2018;168:130-137.
85. Rothmeier AS, Liu E, Chakrabarty S, et al. Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood. 2018;131(6):674-685.
86. Scarabin PY, Vissac AM, Kirzin JM, et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of acti- vated factor VII. Arterioscler Thromb Vasc Biol. 1996;16(9):1170-1176.
87. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coag- ulation factor VII levels in healthy individu- als. Arterioscler Thromb. 1991;11(3):540- 546.
88. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357(9250):101- 105.
89. Eriksson-Berg M, Deguchi H, Hawe E, et al. Influence of factor VII gene polymorphisms
90.
91.
92.
93.
94.
95.
96.
and environmental factors on plasma coag- ulation factor VII concentrations in middle- aged women with and without manifest coronary heart disease. Thromb Haemost. 2005;93(2):351-358.
Mariani G, Bernardi F, Bertina R, et al. Serum phospholipids are the main environ- mental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart". Haematologica. 1999;84(7):620- 626.
Sabater-Lleal M, Almasy L, Martínez- Marchán E, et al. Genetic architecture of the F7 gene in a Spanish population: impli- cation for mapping complex diseases and for functional assays. Clin Genet. 2006;69(5):420-428.
Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand Factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382-1392.
Tang W, Schwienbacher C, Lopez LM, et al. Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease meta-analy- sis. Am J Hum Genet. 2012;91(1):152-162. Taylor KC, Lange LA, Zabaneh D, et al. A gene-centric association scan for coagula- tion factor VII levels in european and African Americans: the candidate gene association resource (CARe) consortium. Hum Mol Genet. 2011;20(17):3525-3534. Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated fac- tor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb. 1994;14(2): 265-274.
Olson NC, Raffield LM, Lange LA, et al. Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk. J Thromb Haemost. 2018;16(1):19-30.
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease. Thromb Res. 2020;189:140-146.
99. Merlini PA, Ardissino D, Oltrona L, Broccolino M, Coppola R, Mannucci PM. Heightened thrombin formation but nor- mal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1995;15(10): 1675-1679.
100.Holm J, Tödt T, Berntorp E, Erhardt L. Failure of thrombolytic therapy in patients with myocardial infarction is associated with high plasma levels of factor VII anti- gen. Thromb Haemost. 1998;79(5):928- 931.
101. Folsom AR, Cushman M, Heckbert SR, Ohira T, Rasmussen-Torvik L, Tsai MY. Factor VII coagulant activity, factor VII - 670A/C and -402G/A polymorphisms, and risk of venous thromboembolism. J Thromb Haemost. 2007;5(8):1674-1678.
102. Roldán V, Marín F, González-Conejero R, et al. Factor VII -323 decanucleotide D/I poly- morphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. Ann Med. 2008;40(7):553-559.
103. D'Ambrosio RL, D'Andrea G, Cappucci F, et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica. 2004;89 (12):1510-1516.
104. Buxhofer-Ausch V, Olcaydu D, Gisslinger B, et al. Decanucleotide insertion polymor- phism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol. 2014;93 (2):103-111.
105.Ken-Dror G, Drenos F, Humphries SE, et al. Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost. 2010;8(11):2394-2403.
106. Donati MB, Zito F, Castelnuovo AD, Iacoviello L. Genes, coagulation and cardio- vascular risk. J Hum Hypertens. 2000;14(6): 369-372.
107.Bernardi F, Arcieri P, Bertina RM, et al. Contribution of factor VII genotype to acti- vated FVII levels. Differences in genotype frequencies between northern and south- ern European populations. Arterioscler Thromb Vasc Biol. 1997;17(11):2548-2553.
97.Martinelli N, Girelli D, Baroni M, et al. Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. J Thromb Haemost. 2016;14(4):655-666.
98. Baroni M, Martinelli N, Lunghi B, et al.
362
haematologica | 2021; 106(2)